기업 정보 불러오는 중
Just reported
Q3 2026 results
From Immunome's results release of 2026년 11월 9일; its quarterly report has since been filed.
Revenue
Actual
US$0.00
Guided
—
No guide given
EPS, GAAP
Actual
-US$0.76
Guided
—
No guide given
Operating income, GAAP
Actual
-US$90.4M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Immunome is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.US$47.6BA+
EXELExelixis, Inc.US$16.8BA+
JAZZJazz Pharmaceuticals plcUS$15.5BA
TECHBIO-Techne CorpUS$11.4BA+
HALOHalozyme Therapeutics, Inc.US$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026년 10월 21일CBGraded C, now B
MCKMckesson Corporation2026년 11월 4일BAGraded B, now A
CVSCVS Health Corp2026년 11월 4일BAGraded B, now A
EWEdwards Lifesciences Corporation2026년 11월 4일BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026년 10월 28일CAGraded C, now A
어떻게 돈을 버는가
- Research collaboration payments (historical)
경쟁 상대
- MKKGYMerck KGaA (through SpringWorks Therapeutics)
- MRKMerck & Co.A
- 규모
- US$364.3B
- 이익률
- 3.6%
- 2616CStone Pharmaceuticals
- NVSNovartisA
- 규모
- US$306.3B
- 이익률
- -0.1%
- CATXPerspective Therapeutics
- 규모
- US$114.3M
- Ratio Therapeutics
무엇을 파는가6
Varegacestat
An investigational, once-daily pill being developed to treat desmoid tumors, which can grow into nearby tissue.
IM-1021
An experimental antibody-drug conjugate designed to carry cancer-killing medicine to cells with the ROR1 marker; it is being tested in people with lymphoma and solid tumors.
IM-1617
An experimental antibody-drug conjugate designed to target a receptor found on some solid tumors.
3개 더 보기
IM-3050
An experimental treatment that uses a molecule aimed at the FAP marker to deliver radioactive lutetium-177 to cells in solid tumors.
IM-1340
An experimental antibody-drug conjugate being developed for solid tumors, including some lung and prostate cancers.
IM-1335
An experimental antibody-drug conjugate being developed to treat solid tumors; its target has not been publicly named.
누가 사는가1
- AbbVie paid for research work under a collaboration agreement that ended in July 2025 (high confidence); Immunome has not reported product-sale customers.
무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가
사업이 기대고 있는 것
- 1Immunome relies on outside manufacturers for materials used in its named drug programs and expects to rely on them for future commercial supply.
- 2The IM-3050 clinical trial depends on third-party diagnostic radiotracer supply; its treatment also requires radioactive lutetium-177.
- 3Varegacestat is licensed from Bristol Myers Squibb, and Immunome owes that company royalties and potential milestone payments if the drug is developed and sold.
잘못될 수 있는 일
- 1Varegacestat has not received marketing approval; the Food and Drug Administration could reject its application or require more information before a decision.
- 2Immunome has no product-sale revenue, reports continuing losses, and expects to need additional financing to fund development and potential commercialization.
- 3Drug development results are uncertain: clinical trials may not show adequate safety or benefit, and early results may not predict later trial outcomes.
Immunome Inc. 소개
Immunome develops medicines intended to treat cancer. Its main drug candidate, varegacestat, is an investigational pill for desmoid tumors; the company has submitted a marketing application in the United States. Its other experimental treatments include drugs designed to deliver cancer-killing medicine or radiation to tumors.
- 본사
- Exton, Pennsylvania, United States
- 설립
- 2006
- 상장 시장
- Nasdaq
- 회계연도 종료
- December 31
Immunome Inc.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.
